A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Study Purpose:

Single ascending doses of AP-101 will be administered by intravenous (IV) infusion

Study Status:

Not recruiting


Amyotrophic Lateral Sclerosis

Study Type:


Type of Intervention:


Intervention Name:





Phase 1

Study Chair(s)/Principal Investigator(s):

Study Director, AL-S Pharma SA

Clinicaltrials.gov ID:


Neals Affiliated?


Coordinating Center Contact Information

Study Sponsor:

AL-S Pharma

Estimated Enrollment:


Estimated Study Start Date:

10 / 10 / 2019

Estimated Study Completion Date:

11 / 02 / 2020

Posting Last Modified Date:

10 / 27 / 2020

Date Study Added to neals.org:

06 / 11 / 2019

Minimum Age:

18 Years

Maximum Age:


Inclusion Criteria:

- All participants must adhere to contraception restrictions

- Female patients of non-childbearing potential due to:

1. Menopause: spontaneous amenorrhea for at least 12 months not induced by a medical conditions such as anorexia nervosa and not taking medications that induced the amenorrhea (e.g., oral contraceptives, hormones, gonadotropin releasing hormones, anti-estrogens, selective estrogen receptor modulators, or chemotherapy)

2. Surgical sterilization

- Have possible, probable, probable laboratory supported or definite and definite familial laboratory-supported ALS in accordance with the El-Escorial criteria

- Have familial or sporadic ALS.

- With onset of ALS symptoms, specifically onset of muscle weakness within past 48 months

- Have slow vital capacity (SVC) of (greater than or equal to) ≥60%

- If on riluzole, must be on a stable dose

- If on edaravone, must have completed 2 cycles and are expected to remain on the same dose throughout the study

- Able to provide informed consent. If the patient is not able to provide written consent due to aggravation of disease condition, written informed consent may be provided by a legally authorized representative

- Have venous access sufficient to allow for blood sampling

- Have clinical laboratory test results within normal reference range for the population or study site, or results with acceptable deviations that are judged to be not clinically significant

Exclusion Criteria:

- Are currently enrolled in, or discontinued from, within the last 30 days, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study

- Have previously completed or withdrawn from this study

- Have a history or presence of medical illness including, but not limited to, any cognitive, cardiovascular, hepatic, hematological, renal, endocrine, or psychiatric, or any clinically significant laboratory abnormality that indicates a medical problem that would preclude study participation

- Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies

- Show evidence of hepatitis C and/or positive hepatitis C antibody

- Show evidence of hepatitis B and/or positive hepatitis B surface antigen

- Are women who are lactating.

- Have undergone a tracheostomy unless it was removed at least 6 months prior

- Are on feeding tube, unless the insertion of a feeding tube is considered prophylactic

- Are on nasal intermittent positive pressure ventilation (NIPPV) >4 hours per day or at the discretion of the medical monitor

- Have undergone stem cell therapy

London Health Sciences Centre, University Hospital

London, Ontario N6A 5A5

Sunnybrook Health Sciences Centre, Toronto

Toronto, Ontario M4N 3M5

Montreal Neurological Institute & Hospital

Montréal, Quebec H3A 2B4